The Power of Women and Entrepreneurship
Once upon a time in a bustling city in India, a young girl named Kiran Mazumdar Shaw was born into a middle-class family. From a tender age, Kiran possessed a relentless curiosity and a passion for science that set her apart from her peers. Her parents nurtured her inquisitive mind, encouraging her to pursue her dreams and never settle for less. As Kiran grew older, she realized the power of education and the transformative potential it held. She pursued a degree in zoology, but fate had something else in store for her. Despite her love for science, Kiran faced countless rejections when she sought a job in the field. Undeterred, she took this setback as an opportunity to explore new horizons. With an unwavering spirit and an entrepreneurial mindset, Kiran recognized the untapped potential in the biotechnology sector. In 1978, armed with determination and a mere $500, she established Biocon—a biotechnology company operating out of her garage.
If you have ever stepped into a pharmacy in India, it is highly likely that you have come across medicines on the shelves that owe their existence, at least in part, to the contributions of Biocon. As the largest biopharmaceutical company in the country, Biocon Limited has made significant strides under the leadership of Kiran Mazumdar Shaw. Not only is she recognized as one of India's wealthiest women, but she also holds the position of chairperson within the company.
Biocon's noteworthy achievements in clinical research have led to numerous breakthroughs, resulting in the company being granted over 1,280 patents. To delve deeper into the remarkable success story of Kiran Mazumdar Shaw, read on and discover more about her inspiring journey.
Early life
Born into a Gujarati family in Maharashtra, the founder of Biocon, Kiran Mazumdar Shaw, embarked on a remarkable educational journey. She received her schooling at Bishop Cotton Girls High School in Bangalore before pursuing her studies at Mount Carmel College. In 1973, she graduated from Bangalore University with a degree in zoology. While her initial aspirations were set on attending medical school, a scholarship altered her path.
From an early age, Kiran Mazumdar Shaw had a passion for research. Encouraged by her father, who held the position of head brewmaster at United Breweries and recognized her thirst for knowledge, she ventured into the field of fermentation science. Under her father's guidance, she pursued studies in brewing and malting at Melbourne University in Australia. In 1975, she emerged as a distinguished master brewer, ranking at the top of her class and becoming the sole woman to graduate from her program.
Following her graduation, Kiran Mazumdar Shaw held various positions, including trainee brewer at Carlton and United Breweries and trainer master at Barret Brothers and Burston in Australia. Equipped with enhanced skills, she returned to India and worked as a trainee consultant at Jupiter Breweries in Calcutta, followed by a role as a technical manager at Standard Maltings Corporation in Baroda.
Despite aspiring to advance her career in Delhi or Bangalore, Kiran Mazumdar Shaw faced challenges as a woman striving to make her mark in the late 20th century. Fortunately, numerous overseas opportunities began to emerge, opening new avenues for her professional growth.
Pathway to Achievement
During her time abroad, Kiran Mazumdar Shaw encountered Leslie Auchincloss, an entrepreneur from Ireland, who sought to establish an Indian subsidiary of his company, Biocon Biochemicals Ltd. This subsidiary specialized in creating enzymes for applications in food packaging, textiles, and brewing.
Intrigued by the opportunity, Kiran Mazumdar Shaw expressed her interest but only if she could hold a position equivalent to her current one. This unexpected turn of events led her to affectionately refer to herself as an accidental entrepreneur.
Mrs. Shaw and Mr. Auchincloss ventured into enzyme production, and upon her return to India, she started Biocon in a rented house garage with a capital of just INR 10,000. Due to regulatory limitations on foreign ownership (capped at 30%), Kiran held 70% ownership of the company. Over time, Biocon expanded into the manufacturing of pharmaceutical drugs alongside enzyme sales, utilizing the generated revenue for research and production.
At that time, venture funding was scarce in the country, compelling Mrs. Shaw to develop a business model focused on revenue and profitability. Overcoming challenges as a woman entrepreneur, she also faced obstacles in securing loans. However, she eventually found a supportive banker who provided financial backing to Biocon. The company experienced significant growth when Biocon India became the nation's first exporter of enzymes to the United States and Europe.
In her first year with Biocon, Kiran Mazumdar Shaw used her earnings to purchase a 20-acre property, facilitating the expansion of her business. Under her leadership, Biocon transformed from a limited manufacturer of industrial enzymes to a fully integrated biopharmaceutical company. Today, Biocon conducts research in the areas of diabetes, auto-immune diseases, and oncology.
Mrs. Shaw went on to establish two subsidiaries: Syngene in 1994, focusing on early-stage research and development support, and Clinigene in 2004, conducting clinical research trials and developing generic and innovative medicines. Eventually, these two subsidiaries merged under Clinigene, which was listed on the Bombay Stock Exchange and the National Stock Exchange in 2015, with a market cap of INR 14,170 crores.
In 1998, Kiran Mazumdar Shaw married John Shaw, who became Biocon's first vice-chairman in 2001. John personally raised USD 2 million to repurchase Biocon's outstanding shares from Imperial Chemical Industries, which had acquired them from Unilever in 1997.
Credit goes to Narayan Murthy for advising Kiran Mazumdar Shaw to list Biocon shares on the stock markets. Motivated by the need to raise capital for research programs, Biocon became the first Indian biotech company to issue an oversubscribed IPO, attracting 33 times the demand. On its first day of trading, Biocon achieved a market value of USD 1.1 billion, making it the second Indian company to cross the USD 1 billion threshold on its debut in the stock market.
Concluding Reflections
Kiran Mazumdar Shaw's journey is an inspiring tale of achievement, perseverance, and unwavering dedication. With her visionary perspective and profound understanding of the value of research and development, she propelled Biocon towards unprecedented growth.
What's Your Reaction?
